The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer.

Our understanding of the molecular mechanisms underlying the pharmacological actions of estrogen receptor (ER) ligands has evolved considerably in recent years. Much of this knowledge has come from a detailed dissection of the mechanism(s) of action of the Selective Estrogen Receptor Modulators (SERMs) tamoxifen and raloxifene, so called for their ability to function as ER agonists or antagonists depending on the tissue in which they operate. These mechanistic insights have had a significant impact on the discovery of second generation SERMs, some of which are in late stage clinical development for the treatment/prevention of breast cancer as well as other estrogenopathies. In addition to the SERMs, however, have emerged the Selective Estrogen Degraders (SERDs), which as their name suggests, interact with and facilitate ER turnover in cells. One drug of this class, fulvestrant, has been approved as a third line treatment for ER-positive metastatic breast cancer. Whereas the first generation SERMs/SERDs were discovered in a serendipitous manner, this review will highlight how our understanding of the molecular pharmacology of ER ligands has been utilized in the development of the next generation of SERMs/SERDs, some of which are likely to have a major impact on the pharmacotherapy of breast cancer.

[1]  M. Lichinitser,et al.  CONFIRM: A Phase III, Randomized, Parallel-Group Trial Comparing Fulvestrant 250 mg vs Fulvestrant 500 mg in Postmenopausal Women with Estrogen Receptor-Positive Advanced Breast Cancer. , 2009 .

[2]  M. Sikora,et al.  The androgen metabolite 5α-androstane-3β,17β-diol (3βAdiol) induces breast cancer growth via estrogen receptor: implications for aromatase inhibitor resistance , 2009, Breast Cancer Research and Treatment.

[3]  S. Robinson,et al.  Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. , 1988, Cancer research.

[4]  M. Harper,et al.  Contrasting Endocrine Activities of cis and trans Isomers in a Series of Substituted Triphenylethylenes , 1966, Nature.

[5]  Joseph P. Costantino,et al.  Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer , 2010, Cancer Prevention Research.

[6]  H. Wilkinson,et al.  Distinct effects of the antiestrogen Faslodex on the stability of estrogen receptors-alpha and -beta in the breast cancer cell line MCF-7. , 2004, Journal of molecular endocrinology.

[7]  D. McDonnell,et al.  A negative coregulator for the human ER. , 2002, Molecular endocrinology.

[8]  J. Gustafsson,et al.  Transcriptional targets shared by estrogen receptor- related receptors (ERRs) and estrogen receptor (ER) alpha, but not by ERbeta. , 1999, The EMBO journal.

[9]  Zbigniew Dauter,et al.  Molecular basis of agonism and antagonism in the oestrogen receptor , 1997, Nature.

[10]  R. Turner,et al.  Tamoxifen prevents the skeletal effects of ovarian hormone deficiency in rats , 1987, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[11]  D. Wheeler,et al.  Novel estrogen response elements identified by genetic selection in yeast are differentially responsive to estrogens and antiestrogens in mammalian cells. , 1994, Molecular endocrinology.

[12]  H. Wilkinson,et al.  Distinct effects of the antiestrogen Faslodex on the stability of estrogen receptors-and-in the breast cancer cell line MCF-7 , 2004 .

[13]  J. Gustafsson,et al.  Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonists. , 1998, Molecular pharmacology.

[14]  B. Wittmann,et al.  Definition of functionally important mechanistic differences among selective estrogen receptor down-regulators. , 2007, Cancer research.

[15]  C. Turner,et al.  Raloxifene preserves bone strength and bone mass in ovariectomized rats. , 1994, Endocrinology.

[16]  Jiong Wu,et al.  ERbeta exerts multiple stimulative effects on human breast carcinoma cells. , 2004, Oncogene.

[17]  Didier Picard,et al.  CARM1 mediates the ligand-independent and tamoxifen-resistant activation of the estrogen receptor alpha by cAMP. , 2010, Genes & development.

[18]  T. Willson,et al.  Structural basis for an unexpected mode of SERM-mediated ER antagonism. , 2005, Molecular cell.

[19]  J. Dixon,et al.  Effects of fulvestrant 750mg in premenopausal women with oestrogen-receptor-positive primary breast cancer. , 2008, European journal of cancer.

[20]  J. Gustafsson,et al.  Differential Response of Estrogen Receptor a and Estrogen Receptor b to Partial Estrogen Agonists/Antagonists , 1998 .

[21]  Carolyn D. DuSell,et al.  27-hydroxycholesterol is an endogenous selective estrogen receptor modulator. , 2008, Molecular endocrinology.

[22]  J. Bryant,et al.  Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. , 2001, Journal of the National Cancer Institute.

[23]  V. Jordan,et al.  Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. , 1988, Cancer research.

[24]  J. Katzenellenbogen,et al.  Minireview: Not picking pockets: nuclear receptor alternate-site modulators (NRAMs). , 2010, Molecular endocrinology.

[25]  A. Lenferink,et al.  Cells HER 2-overexpressing , Tamoxifen-resistant Breast Cancer Kinases Enhances Tamoxifen Action against B-2 ) and Mitogen-activated Protein erb ( neu Inhibition of HER 2 / Updated , 2000 .

[26]  D. Fowlkes,et al.  Comparative analyses of mechanistic differences among antiestrogens. , 1999, Endocrinology.

[27]  Simak Ali,et al.  Regulation of ERBB2 by oestrogen receptor–PAX2 determines response to tamoxifen , 2009, Nature.

[28]  Stephen Safe,et al.  Non-classical genomic estrogen receptor (ER)/specificity protein and ER/activating protein-1 signaling pathways. , 2008, Journal of molecular endocrinology.

[29]  G. Firestone,et al.  Estrogen Receptor β Inhibits Human Breast Cancer Cell Proliferation and Tumor Formation by Causing a G2 Cell Cycle Arrest , 2004, Cancer Research.

[30]  D. McDonnell,et al.  The Estrogen Receptor ␤-isoform (er␤) of the Human Estrogen Receptor Modulates Er␣ Transcriptional Activity and Is a Key Regulator of the Cellular Response to Estrogens and Antiestrogens* , 2022 .

[31]  S. Hilsenbeck,et al.  Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. , 1995, Journal of the National Cancer Institute.

[32]  J. Robertson Fulvestrant (Faslodex) -- how to make a good drug better. , 2007, The oncologist.

[33]  A. Parent,et al.  Blocking estrogen signaling after the hormone: pyrimidine-core inhibitors of estrogen receptor-coactivator binding. , 2008, Journal of medicinal chemistry.

[34]  D. McDonnell,et al.  Definition of the critical cellular components which distinguish between hormone and antihormone activated progesterone receptor , 1995, The Journal of Steroid Biochemistry and Molecular Biology.

[35]  Jiong Wu,et al.  ERβ exerts multiple stimulative effects on human breast carcinoma cells , 2004, Oncogene.

[36]  I. Ellis,et al.  Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. , 2005, Endocrine-related cancer.

[37]  S. Corson Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes , 2006 .

[38]  M. Dillon,et al.  Coassociation of Estrogen Receptor and p160 Proteins Predicts Resistance to Endocrine Treatment; SRC-1 is an Independent Predictor of Breast Cancer Recurrence , 2009, Clinical Cancer Research.

[39]  D. McDonnell,et al.  The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. , 1999, Endocrinology.

[40]  K. Korach,et al.  Allosteric regulation of estrogen receptor structure, function, and coactivator recruitment by different estrogen response elements. , 2002, Molecular endocrinology.

[41]  F. Couch,et al.  A Two-Gene Expression Ratio of Homeobox 13 and Interleukin-17B Receptor for Prediction of Recurrence and Survival in Women Receiving Adjuvant Tamoxifen , 2006, Clinical Cancer Research.

[42]  J. Font de Mora,et al.  AIB1 Is a Conduit for Kinase-Mediated Growth Factor Signaling to the Estrogen Receptor , 2000, Molecular and Cellular Biology.

[43]  V. Jordan,et al.  A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. , 1977, The Journal of endocrinology.

[44]  J. Gustafsson,et al.  Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. , 1997, Science.

[45]  S. Hilsenbeck,et al.  The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  R B Mazess,et al.  Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. , 1992, The New England journal of medicine.

[47]  Norman Wolmark,et al.  Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. , 2006, JAMA.

[48]  D. McDonnell,et al.  Coregulators in nuclear estrogen receptor action: from concept to therapeutic targeting. , 2005, Molecular interventions.

[49]  M. Ellis,et al.  Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  T. Willson,et al.  Circumventing tamoxifen resistance in breast cancers using antiestrogens that induce unique conformational changes in the estrogen receptor. , 2001, Cancer research.

[51]  P. Canney,et al.  CLINICAL SIGNIFICANCE OF TAMOXIFEN WITHDRAWAL RESPONSE , 1987, The Lancet.

[52]  B. Komm,et al.  Genome-Wide Analysis of Estrogen Receptor α DNA Binding and Tethering Mechanisms Identifies Runx1 as a Novel Tethering Factor in Receptor-Mediated Transcriptional Activation , 2010, Molecular and Cellular Biology.

[53]  S. Barni,et al.  Activity of fulvestrant in HER2-overexpressing advanced breast cancer. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[54]  Jiang Shou,et al.  Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts. , 2008, Cancer research.

[55]  D. Fowlkes,et al.  Peptide antagonists of the human estrogen receptor. , 1999, Science.

[56]  S. Hilsenbeck,et al.  Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. , 2003, Journal of the National Cancer Institute.

[57]  R. Schiff,et al.  Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. , 2004, Journal of the National Cancer Institute.

[58]  B. Katzenellenbogen,et al.  Alteration in the agonist/antagonist balance of antiestrogens by activation of protein kinase A signaling pathways in breast cancer cells: antiestrogen selectivity and promoter dependence. , 1994, Molecular endocrinology.

[59]  B. Komm,et al.  Activity of three selective estrogen receptor modulators on hormone-dependent responses in the mouse uterus and mammary gland , 2008, Molecular and Cellular Endocrinology.

[60]  J. Pike,et al.  Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. , 1995, Molecular endocrinology.

[61]  M. Conaway,et al.  Activation of the MAPK pathway enhances sensitivity of MCF-7 breast cancer cells to the mitogenic effect of estradiol. , 2002, Endocrinology.

[62]  D. Fowlkes,et al.  Comparative Analyses of Mechanistic Differences Among Antiestrogens1. , 1999, Endocrinology.

[63]  A. Howell,et al.  Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer , 1995, The Lancet.

[64]  B. O’Malley,et al.  Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. , 1997, Molecular endocrinology.

[65]  P. Hegde,et al.  A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[66]  K. Grandien,et al.  Printed in U.S.A. Copyright © 1997 by The Endocrine Society Comparison of the Ligand Binding Specificity and Transcript Tissue Distribution of Estrogen Receptors � and � , 2022 .

[67]  Ji-ping Wang,et al.  Adaptive hypersensitivity to estradiol: potential mechanism for secondary hormonal responses in breast cancer patients , 2001, The Journal of Steroid Biochemistry and Molecular Biology.

[68]  Gene W. Yeo,et al.  An RNA code for the FOX2 splicing regulator revealed by mapping RNA-protein interactions in stem cells , 2009, Nature Structural &Molecular Biology.

[69]  J. Hartman,et al.  Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[70]  G. Hortobagyi,et al.  Phase II evaluation of Ly156758 in metastatic breast cancer. , 1988, Oncology.

[71]  L. Hartmann,et al.  Randomized trial of diethylstilbestrol vs. tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis , 1999, Breast Cancer Research and Treatment.

[72]  B. Katzenellenbogen,et al.  Characterization of the pharmacophore properties of novel selective estrogen receptor downregulators (SERDs). , 2010, Journal of medicinal chemistry.

[73]  Y. Maehara,et al.  Sensitivity test for 5-fluorouracil and its analogues, 1-(2-tetrahydrofuryl)-5-fluorouracil, uracil/1-(2-tetrahydrofuryl)-5-fluorouracil (4:1) and 1-hexylcarbamoyl-5-fluorouracil, using the subrenal capsule assay. , 1988, Oncology.

[74]  P. Meltzer,et al.  AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. , 1997, Science.

[75]  S. Cummings,et al.  The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women: Results From the MORE Randomized Trial , 2000 .

[76]  B. Katzenellenbogen,et al.  Coactivator peptides have a differential stabilizing effect on the binding of estrogens and antiestrogens with the estrogen receptor. , 1999, Molecular endocrinology.

[77]  V. Vogel The NSABP Study of Tamoxifen and Raloxifene (STAR) trial , 2009, Expert review of anticancer therapy.

[78]  Charles David Jones,et al.  Effects of a new antiestrogen, keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on LH and prolactin levels. , 1983, Life sciences.

[79]  David A. Agard,et al.  The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of This Interaction by Tamoxifen , 1998, Cell.

[80]  Wei Wang,et al.  A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. , 2004, Cancer cell.